{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:07:26Z","timestamp":1790179646969,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ajpc.2026.101642","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:59:51Z","timestamp":1776441591000},"page":"101642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effects of anti-inflammatory agents on cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7582-5611","authenticated-orcid":false,"given":"A","family":"Perkovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ER","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PM","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KR","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BL","family":"Neuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21 Suppl 1","key":"10.1016\/j.ajpc.2026.101642_bib0001","first-page":"II2","article-title":"Inflammation as a cardiovascular risk factor","volume":"109","author":"Willerson","year":"2004","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.ajpc.2026.101642_bib0002","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ajpc.2026.101642_bib0003","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101642_bib0004","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jacc.2023.05.055","article-title":"Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week","volume":"82","author":"Nelson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2026.101642_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-079061","article-title":"Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial","volume":"385","author":"Li","year":"2024","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101642_bib0006","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in Acute Myocardial Infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"issue":"10448","key":"10.1016\/j.ajpc.2026.101642_bib0007","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(24)00968-1","article-title":"Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial","volume":"404","author":"Kelly","year":"2024","journal-title":"Lancet"},{"issue":"10413","key":"10.1016\/j.ajpc.2026.101642_bib0008","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(23)01689-6","article-title":"Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial","volume":"402","author":"Conen","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ajpc.2026.101642_bib0009","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with Canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101642_bib0010","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ajpc.2026.101642_bib0011","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2026.101642_bib0012","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ajpc.2026.101642_bib0013","unstructured":"StataCorp. 2023. Stata 18. Statistical software. StataCorp LLC."},{"issue":"23","key":"10.1016\/j.ajpc.2026.101642_bib0014","first-page":"2787","article-title":"Low dose colchicine for secondary prevention of cardiovascular disease [LoDoCo]: a randomized controlled trial","volume":"126","author":"Nidorf","year":"2012","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.ajpc.2026.101642_bib0015","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ajpc.2026.101642_bib0016","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ajpc.2026.101642_bib0017","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial","volume":"312","author":"O'Donoghue","year":"2014","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.ajpc.2026.101642_bib0018","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","article-title":"Darapladib for preventing ischemic events in stable coronary heart disease","volume":"370","author":"Investigators","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101642_bib0019","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jama.2013.282836","article-title":"Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial","volume":"311","author":"Nicholls","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ajpc.2026.101642_bib0020","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2006.10.039","article-title":"Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease","volume":"99","author":"Nidorf","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ajpc.2026.101642_bib0021","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2022.06.028","article-title":"Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: a combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies","volume":"363","author":"Sun","year":"2022","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101642_bib0022","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1210\/jc.2010-0286","article-title":"Inhibition of protein kinase cbeta does not improve endothelial function in type 2 diabetes","volume":"95","author":"Beckman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ajpc.2026.101642_bib0023","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4172\/2155-6156.1000225","article-title":"Orally-administered chemokine receptor CCR2 antagonist CCX140-B in type 2 diabetes: a pilot double-blind, randomized clinical trial","volume":"3","author":"Hanefeld","year":"2012","journal-title":"J Diabetes Metab"},{"issue":"17","key":"10.1016\/j.ajpc.2026.101642_bib0024","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jacc.2007.11.079","volume":"51","author":"Mohler","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101642_bib0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13075-020-02340-7","article-title":"The Janus kinase 1\/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis","volume":"22","author":"Thudium","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"27","key":"10.1016\/j.ajpc.2026.101642_bib0026","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/eurheartj\/ehu203","article-title":"Anti-inflammatory therapies for cardiovascular disease","volume":"35","author":"Ridker","year":"2014","journal-title":"Eur Heart J"},{"issue":"10289","key":"10.1016\/j.ajpc.2026.101642_bib0027","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"issue":"38","key":"10.1016\/j.ajpc.2026.101642_bib0028","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.ajpc.2026.101642_bib0029","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101642_bib0030","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/ehjcvp\/pvae100","article-title":"A pairwise and network meta-analysis of anti-inflammatory strategies after myocardial infarction: the TITIAN study","volume":"11","author":"Laudani","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"26","key":"10.1016\/j.ajpc.2026.101642_bib0031","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1093\/eurheartj\/ehaf210","article-title":"Colchicine for secondary prevention of vascular events: a meta-analysis of trials","volume":"46","author":"d'Entremont","year":"2025","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.ajpc.2026.101642_bib0032","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101642_bib0033","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ackd.2019.01.004","article-title":"Immune dysfunction and risk of infection in chronic kidney disease","volume":"26","author":"Syed-Ahmed","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4","key":"10.1016\/j.ajpc.2026.101642_bib0034","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/j.1523-1755.2000.00337.x","article-title":"Mortality caused by sepsis in patients with end-stage renal disease compared with the general population","volume":"58","author":"Sarnak","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.ajpc.2026.101642_bib0035","series-title":"USRDS Annual Data Report: Epidemiology of kidney disease in the United States","year":"2023"},{"issue":"18","key":"10.1016\/j.ajpc.2026.101642_bib0036","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jacc.2024.08.052","article-title":"Adjudication of hospitalizations and deaths in the IRONMAN trial of intravenous iron for heart failure","volume":"84","author":"Cleland","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.ajpc.2026.101642_bib0037","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","article-title":"From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?","volume":"117","author":"Ridker","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ajpc.2026.101642_bib0038","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2023. Identifier NCT06118281, ARTEMIS - A research study to look at how Ziltivekimab works compared to placebo in people with a heart attack (ARTEMIS); [cited 2025 Jan 26]; [approximately 98 pages]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06118281?term=ARTEMIS&aggFilters=status:not&rank=3#study-overview."},{"key":"10.1016\/j.ajpc.2026.101642_bib0039","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2022. Identifier NCT05636176, A research study to look at how Ziltivekimab works compared to placebo in people with heart failure and inflammation (HERMES) [cited 2024 Jan 5]; [approximately 105 pages]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05636176."},{"key":"10.1016\/j.ajpc.2026.101642_bib0040","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2022. Identifier NCT05485961, Combined dose-finding and CV outcomes study with CSL300 (Clazakizumab) in adult subjects with ESKD undergoing dialysis [cited 2023 Oct 15]; [approximately 70 pages]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05485961."}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726002175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726002175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:21:51Z","timestamp":1789039311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667726002175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"alternative-id":["S2666667726002175"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101642","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of anti-inflammatory agents on cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101642"}}